Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company focused on oncology genetics testing and information services. This news page aggregates company announcements, conference presentations, financial updates, and other disclosures that relate to NeoGenomics’ role in precision oncology and testing laboratories.
Readers can find earnings and financial news, including quarterly and preliminary full-year revenue updates furnished through press releases and Form 8-K filings. These items describe trends in clinical test volumes, next-generation sequencing (NGS) revenue, and other aspects of the company’s oncology testing business.
The news feed also features scientific and clinical research updates. NeoGenomics regularly announces data presentations at major oncology and hematology meetings, such as the San Antonio Breast Cancer Symposium, the American Society of Hematology Annual Meeting, the International Society of Liquid Biopsy Annual Congress, and the European Society for Medical Oncology Congress. These updates often highlight molecular residual disease (MRD) studies using RaDaR assays, comprehensive genomic profiling in myeloid malignancies, and liquid biopsy-based genomic profiling across solid tumors.
In addition, investors and clinicians can follow corporate and governance developments, including board appointments, executive transitions, and participation in investor conferences. Together, these news items provide a view into how NeoGenomics advances its oncology diagnostics platforms, supports pharmaceutical partners and academic collaborators, and manages its public-company responsibilities. For ongoing insight into NEO stock-related developments and oncology testing initiatives, this page serves as a centralized news resource.
NeoGenomics (NASDAQ: NEO) launched PanTracer Pro, an integrated diagnostic offering for advanced-stage solid tumors combining broad genomic profiling, diagnosis-directed IHC, and ancillary tests.
The test covers more than 500 cancer-related genes, has an expected turnaround time of 8–10 days, and can automatically reflex to PanTracer LBx liquid biopsy when tissue is insufficient.
NeoGenomics (NASDAQ: NEO) will report its fourth quarter and full year 2025 financial results before U.S. markets open on Tuesday, February 17, 2026. Management will host a webcast and conference call at 8:30 a.m. ET to discuss results and recent highlights. The live webcast is available via the Investor Relations website at ir.neogenomics.com and will be archived for replay shortly after the call. Telephone access is available at (888) 506-0062 (domestic) or (973) 528-0011 (international) with participant access code 825997. Attendees are asked to dial in at least five minutes before the call.
NeoGenomics (NASDAQ:NEO) expects preliminary unaudited Q4 2025 revenue of ~$190 million (≈11% YoY) and preliminary unaudited full‑year 2025 revenue of ~$727 million (≈10% YoY). The company noted these are preliminary estimates and subject to change pending year‑end close and audit; final results will be reported on the company’s February 2026 earnings call. NeoGenomics also announced a CFO succession: Abhishek Jain joins as EVP on January 12, 2026, will become CFO on March 2, 2026, as current CFO Jeff Sherman transitions and retires April 14, 2026.
NeoGenomics (NASDAQ:NEO) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Management is scheduled to present and take part in a Q&A session on Tuesday, January 13, 2026 at 5:15 p.m. PT / 8:15 p.m. ET. Interested parties can view live and archived webcasts on the company’s Investors site at ir.neogenomics.com. The presentation will cover recent company developments and offer a management Q&A for investors and analysts.
NeoGenomics (NASDAQ: NEO) appointed diagnostics and lab services veteran John P. “Jack” Kenny to its Board of Directors, effective December 30, 2025, filling the seat of Alison Hannah, MD, who is rotating off after more than ten years.
Mr. Kenny brings 30+ years of executive, commercial, and operational experience, most recently as CEO and president of Meridian Bioscience, and prior senior roles at Siemens Healthcare, Becton Dickinson, Quest, Abbott, and Leica. The board expects his commercial leadership to support growth in NGS and MRD cancer testing and community-setting expansion.
NeoGenomics (NASDAQ:NEO) said Natera voluntarily dismissed its appeal in ongoing RaDaR patent litigation, leaving in place an August 2025 North Carolina federal court ruling in NeoGenomics’ favor.
The District Court granted NeoGenomics’ motion for summary judgment, held Natera’s asserted patent claims invalid as ineligible subject matter, dismissed Natera’s claims with prejudice, and entered a declaratory judgment of invalidity for both asserted patents. NeoGenomics said the dismissal allows it to focus on a full U.S. clinical launch of RaDaR ST in Q1 2026.
NeoGenomics (NASDAQ: NEO) will present new circulating tumor DNA (ctDNA) data from its RaDaR 1.0 assay at the 2025 San Antonio Breast Cancer Symposium (Dec 9–12, 2025).
Presentations include 5-year CLEVER follow-up data showing RaDaR-detected ctDNA was present in most patients with disseminated tumor cells and frequently preceded clinical recurrence by months, plus interim results from the SURVIVE and SURVIVE HERoes Phase III trials evaluating liquid-biopsy guided follow-up and earlier intervention at molecular relapse.
NeoGenomics (NASDAQ: NEO) will present a real-world study at the 67th ASH Annual Meeting (Dec 6–9, 2025) showing that comprehensive genomic profiling (CGP) using the Neo Comprehensive Myeloid panel can refine diagnosis and inform treatment in myeloid malignancies.
Researchers analyzed 533 patients, integrating molecular results with national clinical data; CGP identified pathogenic changes earlier in about one-third of patients and revealed rare actionable fusions (PDGFRA, PDGFRB, FGFR1, JAK2) that guided targeted therapy decisions. The poster is scheduled for Dec 8, 2025, 6:00–8:00 PM ET in session 908A; attendees can visit Booth #1971 for more information.
NeoGenomics (NASDAQ:NEO) will participate in two investor conferences in late 2025: a company presentation at the Stephens Annual Investment Conference in Nashville on Wednesday, November 19, 2025 at 1:00 pm CT, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on Tuesday, December 2, 2025 at 2:30 pm ET.
Both sessions will offer live and archived webcasts available on the company’s Investor Relations site at ir.neogenomics.com.
NeoGenomics (NASDAQ: NEO) will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025 showing high concordance between its RaDaR ST and RaDaR 1.0 assays for molecular residual disease (MRD) detection across solid tumors.
The bridging study evaluated matched samples from 166 patients across 15 solid tumor types, reporting 97% concordance and equivalent sensitivity for RaDaR ST versus RaDaR 1.0. RaDaR ST currently has Medicare coverage for HR+/HER2- breast cancer (recurrence monitoring >5 years after diagnosis) and HPV- head and neck carcinoma (adjuvant and recurrence monitoring). NeoGenomics expects the launch of RaDaR ST in Q1 2026 and will also present additional posters on whole genome–informed MRD, PanTracer LBx validation, and genomic profiling at ISLB 2025.
FAQ
What is the current stock price of Neogenomics (NEO)?
What is the market cap of Neogenomics (NEO)?
